RemeGen Co. Ltd. Class H ( (HK:9995) ) has shared an update.
RemeGen Co., Ltd. has announced that its board of directors will convene on March 27, 2025, to review and approve the company’s annual results for the year ending December 31, 2024. The meeting will also consider the potential payment of dividends, which could impact shareholder returns and reflect the company’s financial health.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biopharmaceutical industry. The company is listed on the Hong Kong Stock Exchange and focuses on developing innovative therapies for various medical needs.
YTD Price Performance: 12.50%
Average Trading Volume: 2,398,796
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$14.44B
For detailed information about 9995 stock, go to TipRanks’ Stock Analysis page.